News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard March 20, 2024 Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States March 7, 2024 Immunic to Participate in Investor and Scientific Conferences in March February 29, 2024 Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 February 22, 2024 Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update February 15, 2024 Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update Show 5102550100 per page«123456789…35»